A German research team’s discoveries about autoimmune diseases are opening up new possibilities for patients with lupus and ...

A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...

Autoimmune diseases, in which the immune system mistakenly attacks the body's own healthy cells and tissues, often include a ...

Instead, we're recruiting healthy soldiers from disease-free, well donors and equipping them with special targeting systems ...

Autoimmune diseases, where the immune system mistakenly attacks the body's own healthy cells and tissues, often have a preclinical stage before diagnosis that's characterized by mild symptoms or ...

Now, scientists at Stanford University have found that a faulty genetic molecule could be responsible for the immune system misidentifying healthy tissue as a threat. The breakthrough study, published ...

Descartes-15 is under clinical development by Cartesian Therapeutics and currently in Phase I for Autoimmune Disorders.

Dermatomyositis is a chronic autoimmune disease characterised by muscle weakness, skin lesions, and systemic complications.

AKP-11 is under clinical development by Akaal Pharma and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I drugs for Autoimmune Disorders have a 73% phase transition ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in earl ...